| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$179 ) |
| | 2022 | 2019 | EUTROPICS PHARMACEUTICALS | 767C CONCORD AVE | CAMBRIDGE | MA | 02138-1000 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 001 | 4 | NIH | 6/29/2022 | -$179 |
| | 2022 | 2018 | EUTROPICS PHARMACEUTICALS | 767C CONCORD AVE | CAMBRIDGE | MA | 02138-1000 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 002 | 3 | NIH | 6/29/2022 | $0 |
| | 2022 | 2017 | EUTROPICS PHARMACEUTICALS | 767C CONCORD AVE | CAMBRIDGE | MA | 02138-1000 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 000 | 2 | NIH | 6/29/2022 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,000,000 ) |
| | 2019 | 2019 | EUTROPICS PHARMACEUTICALS, INC. | 767 CONCORD AVE | CAMBRIDGE | MA | 02138 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 000 | 4 | NIH | 8/27/2019 | $1,000,000 |
|
| Issue Date FY: 2018 ( Subtotal = $991,179 ) |
| | 2018 | 2018 | EUTROPICS PHARMACEUTICALS, INC. | 767 CONCORD AVE | CAMBRIDGE | MA | 02138 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 000 | 3 | NIH | 8/21/2018 | $991,179 |
|
| Issue Date FY: 2017 ( Subtotal = $998,807 ) |
| | 2017 | 2017 | EUTROPICS PHARMACEUTICALS, INC. | 767 CONCORD AVE | CAMBRIDGE | MA | 02138 | MIDDLESEX | USA | R44CA203610 | Commercializing Praedicare Dx TM platform for guiding cancer treatments | 000 | 2 | NIH | 9/12/2017 | $998,807 |
|
| Issue Date FY: 2011 ( Subtotal = $1,293,789 ) |
| | 2011 | 2011 | EUTROPICS PHARMACEUTICALS INC | 60 GRAMPIAN WAY | DORCHESTER | MA | 02125-1035 | SUFFOLK | USA | R44CA135915 | DEVELOPMENT OF SMALL MOLECULE INHIBITOR OF MCL-1 FOR CANCER TREATMENT | 001 | 3 | NIH | 8/1/2011 | $971,831 |
| | 2011 | 2011 | EUTROPICS PHARMACEUTICALS INC | 60 GRAMPIAN WAY | DORCHESTER | MA | 02125-1035 | SUFFOLK | USA | R44CA135915 | DEVELOPMENT OF SMALL MOLECULE INHIBITOR OF MCL-1 FOR CANCER TREATMENT | 000 | 2 | NIH | 3/7/2011 | $321,958 |
|
| Issue Date FY: 2010 ( Subtotal = $691,769 ) |
| | 2010 | 2010 | EUTROPICS PHARMACEUTICALS INC | 60 GRAMPIAN WAY | DORCHESTER | MA | 02125-1035 | SUFFOLK | USA | R44CA135915 | DEVELOPMENT OF SMALL MOLECULE INHIBITOR OF MCL-1 FOR CANCER TREATMENT | 000 | 2 | NIH | 8/18/2010 | $691,769 |
|
| Issue Date FY: 2008 ( Subtotal = $326,983 ) |
| | 2008 | 2008 | EUTROPICS PHARMACEUTICALS INC | 60 GRAMPIAN WAY | DORCHESTER | MA | 02125 | SUFFOLK | USA | R43CA135915 | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF MCL-1 FOR CANCER TREAMENT | 000 | 1 | NIH | 6/16/2008 | $326,983 |
|
|
